Key result
Ventricular pacing >40% linked to ~90% higher new-onset AF risk in SSS.
Why the study?
New-onset atrial fibrillation is common after dual-chamber pacemaker implantation, but existing prediction models were derived from mixed populations of patients with sick sinus syndrome and atrioventricular block and included heterogeneous pacing strategies.
Does a 5-variable landmark risk prediction model accurately predict device-detected new-onset atrial fibrillation in patients with sick sinus syndrome implanted with a dual-chamber pacemaker under managed ventricular pacing?
Cohort (n=443)
No
Does a 5-variable landmark risk prediction model accurately predict device-detected new-onset atrial fibrillation in patients with sick sinus syndrome implanted with a dual-chamber pacemaker under managed ventricular pacing?
A 5-variable clinical and pacing-burden nomogram evaluated at a 3-month landmark provides moderate-to-good discrimination for predicting 1- to 3-year new-onset atrial fibrillation in sick sinus syndrome patients with dual-chamber pacemakers under managed ventricular pacing.
Answers are grounded in this paper and cite their sources.
May guide intensified AF surveillance in paced sick sinus syndrome; leaves open prospective validation before clinical adoption.
Background New-onset atrial fibrillation ( N OAF) is common after dual-chamber pacemaker implantation, but existing prediction models were derived from mixed populations of patients with sick sinus syndrome (SSS) and atrioventricular block and included heterogeneous pacing strategies. Methods In this single-centre retrospective cohort study, consecutive patients with SSS who received a first permanent Medtronic dual-chamber pacemaker with managed ventricular pacing (MVP) enabled as the default strategy were screened. Patients with atrial fibrillation or an atrial high-rate episode (AHRE) within 3 months after implantation were excluded, and prediction time started at this 3-month landmark, with atrial pacing percentage (AP%) and ventricular pacing percentage (VP%) measured at that visit. Patients implanted in 2015–2021 formed the development cohort ( n = 322), and those implanted in 2022–2025 formed a temporal validation cohort ( n = 121) reserved exclusively for validation. Twenty-six candidate predictors were assessed by univariable and multivariable Cox regression with backward Akaike information criterion (AIC) selection. Internal validation repeated the complete model-building procedure within 2,000 bootstrap samples. Temporal performance was assessed using discrimination and calibration at 1, 2 and 3 years after the landmark. Results NOAF occurred in 90 of 322 development patients (28.0%) during a median follow-up of 41.6 months [interquartile range (IQR), 13.7–80.1], and in 28 of 121 temporal validation patients (23.1%) during a median follow-up of 30.5 months (IQR, 8.8–45.9). Age (hazard ratio [HR] per year, 1.043; 95% confidence interval [CI], 1.019–1.067), maximum P-wave duration (Pmax; HR per 10 ms, 1.200; 95% CI, 1.085–1.326), left atrial volume index (LAVi; HR per 1 mL/m2, 1.051; 95% CI, 1.030–1.073), AP% > 50% (HR, 1.845; 95% CI, 1.198–2.840) and VP% > 40% (HR, 1.898; 95% CI, 1.045–3.446) were independently associated with NOAF. The apparent C-index was 0.735; repeating the complete model-building procedure within 2,000 bootstrap samples gave a mean optimism of 0.036 and an optimism-corrected C-index of 0.6992. In temporal validation the C-index was 0.769 (95% CI, 0.639–0.873) and cumulative/dynamic AUC values were 0.753, 0.881 and 0.916 at 1, 2 and 3 years after the landmark. Calibration-in-the-large was −0.17, 0.24 and 0.35 and calibration slopes were 0.90, 0.99 and 0.98 at 1, 2 and 3 years, respectively. The 1-year calibration estimate remained least precise, with only five NOAF events by 1 year in the validation cohort. Conclusion In patients with SSS who remained free of atrial arrhythmia through the 3-month post-implantation landmark, a five-variable landmark model showed moderate optimism-corrected discrimination in the development cohort and promising same-centre temporal validation performance, particularly at 2 and 3 years after the landmark. The limited number of validation events, particularly at 1 year, warrants cautious interpretation. Prospective multicentre external validation is required before clinical implementation.
No takes yet. Share an insight, caveat, or question.
Xie et al. (2026) conducted a cohort in Sick sinus syndrome with first permanent dual-chamber pacemaker implantation under managed ventricular pacing (n=443). Five-variable landmark risk prediction model (age, Pmax, LAVi, AP% >50%, and VP% >40% at 3 months) vs. Lower-risk profile / ventricular pacing ≤40% (or reconstructed CHA2DS2-VASc score benchmark) was evaluated on Device-detected new-onset atrial fibrillation (NOAF) after the 3-month post-implantation landmark (reported here for the multivariable association of ventricular pacing >40%) (HR 1.898, 95% CI 1.045-3.446, p=0.0353). A 5-variable landmark model predicted device-detected new-onset AF in SSS patients with a temporal validation C-index of 0.769.
Synapse has enriched 10 related papers. Consider them for comparative context: